Literature DB >> 19158315

Receptor occupancy and brain free fraction.

Jeanette Watson1, Sara Wright, Adam Lucas, Kirsten L Clarke, Jean Viggers, Sharon Cheetham, Phil Jeffrey, Rod Porter, Kevin D Read.   

Abstract

This study was designed to investigate whether brain unbound concentration (C(u,brain)) is a better predictor of dopamine D(2) receptor occupancy than total brain concentration, cerebrospinal fluid concentration (C(CSF)), or blood unbound concentration (C(u,blood)). The ex vivo D(2) receptor occupancy and concentration-time profiles in cerebrospinal fluid, blood, and brain of six marketed antipsychotic drugs were determined after oral administration in rats at a range of dose levels. The C(u,brain) was estimated from the product of total brain concentration and unbound fraction, which was determined using a brain homogenate method. In conclusion, the C(u,brain) of selected antipsychotic agents is a good predictor of D(2) receptor occupancy in rats. Furthermore, C(u,brain) seems to provide a better prediction of D(2) receptor occupancy than C(CSF) or C(u,blood) for those compounds whose mechanism of entry into brain tissue is influenced by factors other than simple passive diffusion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158315     DOI: 10.1124/dmd.108.022814

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  22 in total

1.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.

Authors:  I Loryan; E Melander; M Svensson; M Payan; F König; B Jansson; M Hammarlund-Udenaes
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

2.  Determination of the unbound fraction of R- and S-methadone in human brain.

Authors:  Karen M D Holm; Kristian Linnet
Journal:  Int J Legal Med       Date:  2016-04-07       Impact factor: 2.686

Review 3.  Choroid Plexus and Drug Removal Mechanisms.

Authors:  Austin Sun; Joanne Wang
Journal:  AAPS J       Date:  2021-05-03       Impact factor: 4.009

4.  Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery.

Authors:  Irena Loryan; Vikash Sinha; Claire Mackie; Achiel Van Peer; Wilhelmus Drinkenburg; An Vermeulen; Denise Morrison; Mario Monshouwer; Donald Heald; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

5.  Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576.

Authors:  Roberta Bursi; Gul Erdemli; Robert Campbell; Matthew M Hutmacher; Thomas Kerbusch; David Spanswick; Ross Jeggo; Kari R Nations; Peter Dogterom; Jacques Schipper; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2011-06-07       Impact factor: 4.530

Review 6.  Probing the links between in vitro potency, ADMET and physicochemical parameters.

Authors:  M Paul Gleeson; Anne Hersey; Dino Montanari; John Overington
Journal:  Nat Rev Drug Discov       Date:  2011-03       Impact factor: 84.694

Review 7.  Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans.

Authors:  Mitchel J R Ruigrok; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2015-02-19       Impact factor: 4.009

Review 8.  In vitro, in vivo and in silico models of drug distribution into the brain.

Authors:  Scott G Summerfield; Kelly C Dong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-13       Impact factor: 2.745

Review 9.  In silico prediction of brain exposure: drug free fraction, unbound brain to plasma concentration ratio and equilibrium half-life.

Authors:  Morena Spreafico; Matthew P Jacobson
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 10.  The Benefits of Olanzapine in Palliating Symptoms.

Authors:  Mellar P Davis; Gareth J Sanger
Journal:  Curr Treat Options Oncol       Date:  2020-11-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.